Market Overview

UPDATE: Morgan Stanley Reiterates Baxter International at Overweight Despite Deal Concerns

Related BAX
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Merck Snags Baxter Executive As CFO (Fox Business)

Morgan Stanley maintained its Overweight rating on Baxter International (NYSE: BAX) despite having concerns over the company's latest Gambro acquisition.

Morgan Stanley noted, "Gambro is a good business long-term with positive secular drivers, but near-term bundling and reimbursement pressures are challenging. Recent growth has not been robust and appears to be in the low single digits. It is not clear whether this represents soft end-market fundamentals, a focus on cash flow over growth, or product positioning. Whether Baxter's global scale and investment could accelerate growth is unclear. If media reports are correct, at $4 billion, this transaction is much larger deal than management's previously discussed target size of <$500 million. That said, management's prior comments may have been targeted at higher-risk technology bets, and Gambro is a more mature asset. Even so, this is the largest deal in Baxter's history, and all transactions carry risk."

Baxter International closed at $68.81 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
Oct 2014BarclaysMaintainsOverweight
Oct 2014Credit SuisseMaintainsOutperform
Oct 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional